NIH Funding Opportunities

Sidebar

NIAID - Notice of Special Interest (NOSI): Towards Developing a Cure for HBV in HIV/HBV Co-Infection

The Notice of Special Interest (NOSI) seeks to fill scientific gaps needed to (a) inform HBV cure strategies by furthering our understanding of unique challenges impacting HBV and HIV co-infected hosts; and (b) advance the discovery and development of novel HBV interventions that are safe and achieve a cure in HIV and HBV co-infected individuals.

NOT-AI-22-043

First Available Due Date: September 05, 2022

Expiration Date: May 08, 2025


NIAID- Notice of Special Interest (NOSI): Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP)

The purpose of this Notice is to encourage new applications to support further development of a diverse and comprehensive portfolio of SR/LA products for prevention and treatment of HIV. SR/LA antiretroviral products will have a minimum window of protection of three (3) months from either a single dosing (injection, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.) to reflect current state of SR/LA drug market for HIV treatment or prevention.

NOT- AI-22-042

First Available due date: September 7, 2022

Expiration Date: May 8, 2025


NIAID - Limited Interaction Targeted Epidemiology: Viral Suppression (LITE-VS) (UG3/UH3, Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from investigators to enroll large, digitally-maintained cohorts of people with HIV-1 (PWH) in the United States who are not adequately virally suppressed. Applicants will need to employ sampling strategies that ensure meaningful enrollment of participants who report prior gaps in HIV care engagement and/or lack of sustained viral suppression (VS). The goal is to follow the research cohort over time to prospectively investigate trajectories of HIV care engagement and viral suppression, as well as the temporal antecedents and multilevel factors that drive changes in care engagement, antiretroviral adherence, and viral suppression. Researchers may test strategies for improved methods of screening, enrollment, and retention of cohort participants. Projects should seek to inform future interventions to promote sustained engagement in HIV care and sustained HIV viral suppression, and additionally have the option of testing digitally-delivered interventions toward that end.

RFA-AI-22-024

Application Due: August 3, 2022


Advancing communication strategies to support future HIV vaccine use (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites applications for Research Project Grants (R01) that will advance novel health communication research designed to inform and support acceptance and uptake of future vaccines that protect against HIV. Research should focus on understanding key drivers for HIV vaccine communication success, communication strategies for engagement of communities placed at greatest risk for acquiring HIV, and/or mitigating the impact and reach of HIV vaccine misinformation. Research applications may leverage HIV vaccine analogs (e.g., COVID-19, HPV, HBV vaccines), so long as they have a primary focus on populations placed at risk for HIV, and/or healthcare settings and providers involved in HIV prevention delivery.

RFA-MH-22-170 

Application Due: May 20, 2022

 


Advancing communication strategies to support future HIV vaccine use (R21 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites applications for Research Project Grants (R21) that will advance novel health communication research designed to inform and support acceptance and uptake of future vaccines that protect against HIV. Research should focus on understanding key drivers for HIV vaccine communication success, communication strategies for engagement of communities placed at greatest risk for acquiring HIV, and/or mitigating the impact and reach of HIV vaccine misinformation. Research applications may leverage HIV vaccine analogs (e.g., COVID-19, HPV, HBV vaccines), so long as they have a primary focus on populations placed at risk for HIV, and/or healthcare settings and providers involved in HIV prevention delivery.

RFA-MH-22-171

Application Due: May 10, 2022

 


The role of Epstein Barr virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01 Clinical Trial Optional)

This funding opportunity announcement (FOA) focuses on the role of EBV infection on Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection. The goal is to increase our knowledge through mechanistic, epidemiological, or translational studies that examine how EBV promotes NHL or HD initiation, progression, and the resulting disease sequelae and to provide insights into mechanistic differences in the relationship between EBV infection and lymphomagenesis in HIV+ versus HIV- persons. Research project U01s funded through this PAR will form a cooperative group, the Epstein Barr Virus associated Lymphoma Consortium (EALC).

PAR-21-348

Application Due: December 15, 2022

At a Glance